Wikipedia

User:Mr. Ibrahem/Pitolisant

< User:Mr. Ibrahem
Mr. Ibrahem/Pitolisant
Clinical data
Trade namesWakix, Ozawade, others
Other namesTiprolisant; Ciproxidine; BF2.649
AHFS/Drugs.comMonograph
MedlinePlusa619055
License data
Routes of
administration		By mouth
Drug classHistamine 3 (H3) receptor inhibitor[1]
Legal status
Legal status
Identifiers
  • 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine
Chemical and physical data
FormulaC17H26ClNO
Molar mass295.85 g·mol−1
3D model (JSmol)
  • C1CCN(CC1)CCCOCCCC2=CC=C(C=C2)Cl
  • InChI=1S/C17H26ClNO/c18-17-9-7-16(8-10-17)6-4-14-20-15-5-13-19-11-2-1-3-12-19/h7-10H,1-6,11-15H2 checkY
  • Key:NNACHAUCXXVJSP-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Pitolisant, sold under the brand name Wakix among others, is a medication for the treatment of excessive daytime sleepiness in narcolepsy.[1] It is taken by mouth once a day in the morning.[3][4]

Common side effects include headache, trouble sleeping, nausea, and anxiety.[3] Other side effects may include QT prolongation.[5] Safety in pregnancy is unclear.[6] It bring about an opposite to usual response at the histamine 3 (H3) receptor.[1] This increases the activity of histamine neurons in the brain, which keeps a person awake.[7][3]

Pitolisant was approved for medical use in the United States in 2019 and Europe in 2021.[5][3] In the United Kingdom it costs the NHS about £310 per month as of 2021.[4] In the United States this amount costs about 6,800 USD.[8]

References edit

  1. ^ a b c d e "Wakix- pitolisant hydrochloride tablet, film coated". DailyMed. 6 November 2019. Archived from the original on 11 August 2020. Retrieved 18 August 2020.
  2. ^ "Wakix EPAR". European Medicines Agency (EMA). Archived from the original on 12 November 2020. Retrieved 18 August 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  3. ^ a b c d e f "Ozawade EPAR". European Medicines Agency (EMA). Archived from the original on 15 October 2021. Retrieved 15 October 2021.
  4. ^ a b c BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 513. ISBN 978-0857114105.
  5. ^ a b "Pitolisant Monograph for Professionals". Drugs.com. Archived from the original on 21 January 2021. Retrieved 28 October 2021.
  6. ^ "Pitolisant (Wakix) Use During Pregnancy". Drugs.com. Archived from the original on 18 March 2020. Retrieved 28 October 2021.
  7. ^ Syed YY (20 July 2016). "Pitolisant: First Global Approval". Drugs. 76 (13): 1313–1318. doi:10.1007/s40265-016-0620-1. PMID 27438291. S2CID 42684839.
  8. ^ "Wakix Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 24 January 2021. Retrieved 28 October 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Pitolisant&oldid=1195768283"